A Multicenter, Cross-Sectional, Observational Study on Epilepsy and its Management Practices in India

Mehndiratta, Man Mohan; Sarma, G.R.K.; Tripathi, Manjari; Ravat, Sangeeta; Gopinath, Siby; Babu, Suresh Chandra; Mishra, Upama

doi:10.4103/0028-3886.359162

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent literature shows that a number of studies have been published on the patterns of use of antiepileptic drugs in epilepsy patients in India (6)(7)(8) . These studies focus mainly on the prescribing trends of AEDs as a whole rather than the use of individual drug(s) for distinct epilepsy types.…”

Section: Introductionmentioning

confidence: 99%

Prescribing Pattern of Levetiracetam in Epilepsy Patients: A Cross-Sectional Study in a Tertiary Care Centre in Manipur

Devi¹,

Gobinath²,

Gunindro³

et al. 2023

IJST

View full text Add to dashboard Cite

Objective: The objective is to shed light on the prescribing pattern of levetiracetam, a newer antiepileptic drug, in the treatment of different types of epilepsy. Methods: A record-based cross-sectional study of epilepsy patients who reported to the Therapeutic Drug Monitoring Unit in the Department of Pharmacology, Regional Institute of Medical Sciences, Manipur, was conducted. Case records of patients receiving levetiracetam and reporting from January 2017 to December 2020 were included. The patient's age, gender, and weight; clinical diagnosis; levetiracetam dose; and other co-administered AEDs were all examined. Findings: Of the 17 cases, the majority of the patients were adults, and 52.9% were males. The patients' average body weight (kg) was 49.8 ± 9.4. Generalised tonic-clonic seizures (GTCS) constituted the majority of the cases (47.1%), followed by simple partial seizures, complex partial seizures (23.5% of each), and absence seizures (5.9%). 70.11% of the cases received LEV monotherapy, while the remaining cases were prescribed combination therapy. LEV alone was prescribed in 87.5% of GTCS cases. The median daily dose of LEV was 1000 mg (IQR-625). Novelty : The observation that levetiracetam alone is prescribed in the majority of GTCS cases, the commonest type of epilepsy, is an eye-opener for another new monotherapy option for GTCS.

show abstract

Section: Introductionmentioning

confidence: 99%